Current Report Filing (8-k)
November 14 2022 - 04:47PM
Edgar (US Regulatory)
0001684144false00016841442022-11-142022-11-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
November 14, 2022
|
ZOMEDICA
CORP.
|
|
(Exact name of registrant as specified in its charter)
|
|
Alberta, Canada
|
|
001-38298
|
|
N/A
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
100 Phoenix Drive, Suite 125, Ann Arbor,
Michigan
|
|
48108
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (734)
369-2555
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
|
Common Shares, without par value
|
ZOM
|
NYSE American
|
Item 2.02 Results of Operations and Financial
Condition.
On November 14, 2022, Zomedica Corp. (the “Company”) issued a press
release announcing the Company’s financial results for the quarter
ended September 30, 2022. A copy of the press release is furnished
as Exhibit 99.1 hereto and is incorporated by reference herein.
The information in this Item 2.02, and Exhibit 99.1 attached
hereto, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section.
The information in this current report shall not be incorporated by
reference into any registration statement or other document filed
with the Securities and Exchange Commission, whether filed before
or after the date hereof regardless of any general incorporation
language in any such filing, unless we expressly set forth in such
filing that such information is to be considered “filed” or
incorporated by reference therein.
Item 9.01 Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
ZOMEDICA CORP.
|
|
| |
|
|
|
| Date: November 14, 2022 |
By: |
/s/ Ann Marie
Cotter |
|
|
|
|
Name: Ann Marie Cotter |
|
| |
|
Title: Chief Financial Officer |
|
Exhibit Index
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Jan 2023 to Feb 2023
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Feb 2022 to Feb 2023
